OpGen and Hitachi Enter into an Agreement
News Oct 17, 2013
OpGen, Inc. and Hitachi High-Technologies Corporation today announced an agreement to develop a comprehensive human chromosome mapping analytical service for clinical research applications by a combination of OpGen’s market-leading Whole Genome Mapping™ technology and Hitachi High-Technologies’ and Hitachi group’s cloud-based systems. This service will include bioinformatics tools to complete human genome sequence, and detect and analyze structural variations in human chromosomes.
“Hitachi High-Technologies Corporation is a global technology leader, and we are pleased to partner with them to create an integrated solution for human genome analysis that captures important structural variation information,” said Douglas White, chief executive officer of OpGen, Inc. “The resulting human chromosome mapping service will enable OpGen to continue its expansion into clinical research with the potential to develop diagnostic applications for diseases based on a patient’s genetic information.”
Under the terms of this agreement, Hitachi High-Technologies will fund development, and the companies will work together to combine the strengths of their proprietary technologies. OpGen’s Whole Genome Mapping provides a unique view into structural variation in human chromosomes and offers a more accurate and complete analysis of the human genome than next generation sequencing data alone can provide. Many structural variations are associated with cancer, autism, Alzheimer’s disease and many other cognitive disorders. This type of genetic information will enable development of new therapies, and eventually will empower the broader healthcare community to diagnose and guide treatment decisions based on a patient’s genetic profile.
Hitachi High-Technologies, with recognized experience and achievements through DNA sequencer business in the life science and translational research markets, has been developing the cloud platform for human genome data analysis with Hitachi Solutions, in Foster City, California. The human genome cloud platform will enable secure entry portals for researchers, clinicians, and eventually patients to access Whole Genome Mapping data, human chromosome analytical tools and ultimately, clinically actionable data. As part of the service, Hitachi High-Technologies also will add human DNA sequence analytical tools, which complement Whole Genome Mapping, to provide complete genetic evaluation of human chromosomes.
“This partnership leverages our development of the cloud-based informatics platform and provides enabling and proven technology for human genetic analysis,” said Takashi Matsuzaka, senior vice president and executive officer, CTO of Hitachi High-Technologies Corporation. “This is a great example of how Hitachi High-Technologies is continuously enhancing our healthcare informatics offerings for customers worldwide by partnering our technologies with other innovative companies, such as OpGen.”
OpGen and Hitachi High-Technologies/Hitachi Solutions plan to introduce more details about the service in the Hitachi booths 811 & 813 at the American Society of Human Genetics Annual Meeting, being held October 23-25 in Boston.
Algorithm Speeds Up Medical Image Analysis 1000 TimesNews
Medical image registration is a common technique that involves overlaying two images, such as magnetic resonance imaging (MRI) scans, to compare and analyze anatomical differences in great detail. Researchers have described a machine-learning algorithm that can register brain scans and other 3-D images more than 1,000 times more quickly using novel learning techniques.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE